P-CD19CD20-ALLO1 Cells Clinical Trials
2 recruitingBiologic
Phase 12
Showing 1–2 of 2 trials
Recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus
Genentech, Inc.162 enrolled2 locationsNCT06984341
Recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis
Multiple Sclerosis
Genentech, Inc.60 enrolled1 locationNCT07008378